Annovis Bio Inc. Advances Phase 3 Alzheimer’s Trial and Reports Q2 2025 Financial Results
Annovis Bio Inc. (NYSE: ANVS) makes significant progress in its Phase 3 Alzheimer’s trial and reports improved financial results for Q2 2025, highlighting the potential impact of its neurodegenerative disease therapies.
